Aligned Genetics Inc (238120) — Cash Flow-to-Debt Ratio
Aligned Genetics Inc (238120) has a Cash Flow-to-Debt Ratio of -0.21x as of September 2025, meaning its operating cash flow of ₩-2.04 Billion could theoretically repay 0% of its total liabilities (₩9.61 Billion) in one year. See Aligned Genetics Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Aligned Genetics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Aligned Genetics Inc across 10 annual periods. Also explore Aligned Genetics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Aligned Genetics Inc (2015–2024)
Year-by-year debt coverage analysis for Aligned Genetics Inc. For market capitalisation and broader financial context, see Aligned Genetics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.35x | ₩3.07 Billion | ₩8.78 Billion | ▲ +17.9% |
| 2023 | 0.30x | ₩2.85 Billion | ₩9.62 Billion | ▲ +7.3% |
| 2022 | 0.28x | ₩2.22 Billion | ₩8.05 Billion | ▲ +1417.9% |
| 2021 | 0.02x | ₩135.97 Million | ₩7.48 Billion | ▲ +104.8% |
| 2020 | 0.01x | ₩35.67 Million | ₩4.02 Billion | ▼ -95.1% |
| 2019 | 0.18x | ₩659.29 Million | ₩3.65 Billion | ▲ +121.8% |
| 2018 | -0.83x | ₩-1.75 Billion | ₩2.11 Billion | ▼ -57.3% |
| 2017 | -0.53x | ₩-876.75 Million | ₩1.67 Billion | ▲ +22.6% |
| 2016 | -0.68x | ₩-1.14 Billion | ₩1.68 Billion | ▼ -53.8% |
| 2015 | -0.44x | ₩-351.72 Million | ₩796.04 Million | — |